查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1994259

Eylea市場：2026-2032年全球市場預測（依適應症、給藥頻率、最終用戶和通路分類）

Eylea Market by Indication, Dosage Frequency, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，Eylea 市場價值將達到 77.1 億美元，到 2026 年將成長到 81.9 億美元，到 2032 年將達到 127.5 億美元，複合年成長率為 7.45%。

主要市場統計數據
基準年 2025 77.1億美元
預計年份：2026年 81.9億美元
預測年份：2032年 127.5億美元
複合年成長率 (%) 7.45%

本文全面說明了 Eylea 不斷變化的臨床作用、醫療保健服務的轉型以及影響相關人員決策的分銷考慮因素。

艾力雅（Eylea）是一種廣泛使用的玻璃體內注射抗血管內皮生長因子（VEGF）療法，由於其在多種適應症中療效顯著，以及支付方和醫療服務提供者不斷變化的需求，已成為現代視網膜疾病治療的核心。臨床醫師在選擇藥物時，越來越重視比較給藥間隔、作用持續時間和安全性，艾力雅的臨床應用也經常在此背景下進行評估。同時，給藥場所的變化，從醫院門診到門診手術中心，以及眼科診所在常規注射中作用的不斷增強，正在重塑治療管道。

對受技術進步、保險公司加強監管以及臨床環境變化等因素影響的市場變革進行詳細分析，這些變革影響了 Eylea 的使用。

隨著技術創新、支付方趨勢以及臨床環境的經濟因素重塑治療方法的選擇和實施方式，視網膜治療市場格局正經歷變革性的變化。新的影像技術和真實世界數據正在完善啟動治療的標準，並促成更個人化的給藥決策，進而影響診所的接診能力和病患追蹤頻率。同時，支付方正在加強對用藥模式和預核准流程的監控，這影響著藥物製劑的選擇和在保險覆蓋範圍內的定位。

詳細檢驗2025 年美國關稅將如何影響視網膜治療藥物的供應鏈、籌資策略和分銷穩定性。

關稅和貿易措施的推出會對藥品供應鏈、籌資策略和價格談判產生連鎖反應。 2025年，美國關稅調整影響了製造商和經銷商的庫存規劃、合約談判和進口策略制定，促使他們重新評估成本因素和緊急應變計畫。這些政策變化導致供應商選擇受到更嚴格的監管，並加速了關於本地化生產和近岸外包以降低跨境風險的討論。

實用的細分見解闡明了適應症、治療地點、分銷管道和給藥頻率如何影響 Eylea 的臨床引入和運作策略。

細分市場分析揭示了微妙的市場接受模式和營運影響，有助於臨床、商業和供應鏈決策。就適應症而言，Eylea在老齡化黃斑部病變、視網膜分支靜脈阻塞症、視網膜中央靜脈阻塞、糖尿病性黃斑部水腫和糖尿病視網膜病變的應用各有其獨特的患者特徵、監測要求和長期管理目標，這些因素都會影響治療間隔和隨訪頻率。例如，慢性糖尿病視網膜疾病的治療通常需要與內分泌科醫生和基層醫療密切合作，而靜脈阻塞病例可能需要更頻繁的干涉和基於影像學的追蹤。

基於整合美洲、歐洲、中東和非洲以及亞太地區在監管、保險公司和醫療保健服務體系方面的差異的關鍵區域信息，我們制定針對每個地區的戰略。

區域趨勢對監管流程、支付方結構和臨床實務規範有顯著影響，因此需要採取在地化的商業化和存取策略。在美洲，視網膜領域的集中專業知識和多樣化的支付方模式有利於高品質證據的產生和複雜合約談判，而區域分銷中心和庫存彈性對於供應鏈至關重要。同時，在歐洲、中東和非洲，不同的法規結構和定價機制要求差異化的策略，以促進與國家衛生部門和私人保險公司的對話。

企業層面的洞察，聚焦在視網膜治療領域透過綜合服務交付實現的證據產生、供應鏈韌性和策略差異化。

視網膜治療領域的競爭格局呈現出成熟生物製藥、生物相似藥和新興給藥技術並存的局面，促使各公司優先考慮透過療效數據、患者支持和供應穩定性來實現差異化。主要企業正投資於直接比較試驗、真實世界數據 (RWE) 生成和療效註冊研究，以證明其臨床優勢並支持與支付方的對話。同時，各公司正透過提供可減輕臨床醫生和患者行政負擔的服務來強化其商業性提案，例如簡化核准前流程和協調注射治療流程。

為行業領導者提供實用建議，以協調臨床證據、供應彈性和支付方參與，同時最佳化區域和實踐特定策略。

行業領導者必須採取積極措施，使臨床價值與營運可行性和支付方預期保持一致，從而維持醫療服務的可及性並最佳化患者療效。首先，應加強銷售、醫學事務和供應鏈團隊之間的跨職能協作，確保合約條款、庫存策略和臨床訊息的一致性，並能夠快速應對價格和採購趨勢的變化。這種整合式方法可以降低供應中斷的風險，並在政策或物流發生變化時明確責任歸屬。

我們採用清晰且可重複的調查方法，結合一手訪談、文獻整合和情境分析，嚴格評估臨床和營運趨勢。

本研究整合了多方面的證據，對臨床、營運和商業性趨勢進行了全面評估。主要調查包括對視網膜專家、藥房採購經理和醫療系統管理人員進行結構化訪談，以了解第一線觀點對給藥間隔、臨床應用趨勢和分銷挑戰的看法。次要調查回顧了同行評審的文獻、監管文件和公開的臨床實驗室結果，以檢驗每種適應症（包括老齡化黃斑部病變和糖尿病視網膜病變）的臨床終點和安全性。

為了指導策略決策，確保患者能夠持續獲得治療價值，我們提供了簡潔的結論，這些結論整合了關鍵的臨床、營運和區域問題。

總之，Eylea在現代視網膜疾病管理中發揮核心作用，其臨床證據和給藥模式也不斷發展。給藥頻率偏好、臨床環境變化以及分銷管道的改變，都為製藥公司、醫療服務提供者和保險公司帶來了挑戰和機會。應對這種複雜的環境需要製定一項整合證據產生、供應鏈韌性和與保險公司進行有針對性溝通的策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：艾力亞市場：依適應症分類

  • 老齡化黃斑部病變
  • 視網膜分支靜脈阻塞症
  • 中心性視網膜靜脈阻塞
  • 糖尿病黃斑部水腫
  • 糖尿病視網膜病變

第9章：艾力達市場：依給藥頻率分類

  • 根據需要
  • 每隔一個月
  • 每月

第10章：艾利亞市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 眼科診所

第11章：艾利亞市場：按分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：艾利亞市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：艾利亞市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：艾利亞市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國Eilea市場

第16章：中國的Eilea市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc
  • Adverum BIoTechnologies Inc
  • Alcon Inc
  • Amgen Inc
  • Apellis Pharmaceuticals Inc
  • AstraZeneca plc
  • Bausch Health Companies Inc
  • Bayer AG
  • Biogen Inc
  • Eli Lilly and Company
  • Genentech Inc
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Kodiak Sciences Inc
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd
  • Outlook Therapeutics Inc
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Roche Holding AG
  • Samsung Bioepis Co., Ltd
  • Sanofi SA
  • Santen Pharmaceutical Co., Ltd
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-1A1A064C04F0

The Eylea Market was valued at USD 7.71 billion in 2025 and is projected to grow to USD 8.19 billion in 2026, with a CAGR of 7.45%, reaching USD 12.75 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.71 billion
Estimated Year [2026] USD 8.19 billion
Forecast Year [2032] USD 12.75 billion
CAGR (%) 7.45%

A comprehensive introduction framing Eylea's evolving clinical role, care delivery shifts, and distribution considerations shaping stakeholder decision-making

Eylea, a widely used intravitreal anti-VEGF therapy, has become central to contemporary retinal disease management due to its established efficacy across multiple indications and evolving payer and provider dynamics. Clinicians increasingly weigh comparative dosing cadence, durability, and safety profiles when choosing between available agents, and Eylea's clinical portfolio is routinely evaluated in that context. Concurrently, changes in delivery settings, from hospital-based clinics to ambulatory surgical centers, and the growing role of ophthalmic clinics in routine injections are reshaping care pathways.

Regulatory approvals and label extensions have expanded Eylea's footprint across indications such as Age-Related Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Diabetic Macular Edema, and Diabetic Retinopathy, prompting shifts in treatment algorithms. Meanwhile, distribution dynamics spanning hospital pharmacy, online pharmacy, and retail pharmacy channels influence how institutions procure and dispense therapies. As stakeholders reassess supply arrangements and clinic workflows, an evidence-based understanding of dosing frequency patterns-spanning as needed, bimonthly, and monthly regimens-becomes essential for operational planning and patient adherence strategies.

In this introduction, the focus is to set the stage for deeper analysis by outlining the clinical, operational, and commercial forces that drive Eylea's adoption. By connecting clinical evidence to care delivery realities and distribution structures, readers can better appreciate the levers available to improve patient outcomes while maintaining fiscal and operational resilience.

An in-depth analysis of transformative market shifts driven by technological advances, evolving payer scrutiny, and site-of-care migration impacting Eylea utilization

The landscape for retinal therapeutics is undergoing transformative shifts as technological innovation, payer behavior, and site-of-care economics converge to reshape how therapies are selected and delivered. Newer imaging modalities and real-world evidence are refining treatment thresholds and enabling more personalized dosing decisions, which in turn affect clinic throughput and the cadence of patient follow-up. In parallel, payers are intensifying scrutiny on utilization patterns and prior authorization processes, influencing prescribing behavior and formulary positioning.

Operationally, the migration of procedures to ambulatory surgical centers and specialized ophthalmic clinics has altered cost structures and patient access dynamics. These site-of-care changes create opportunities for efficiencies but also introduce complexities in inventory management across hospital pharmacy, online pharmacy, and retail pharmacy channels. Moreover, evolving expectations around treatment durability have elevated the importance of dosing frequency choices; options ranging from as needed, bimonthly, to monthly regimens carry implications for adherence, clinic capacity, and long-term visual outcomes.

Collectively, these shifts demand that manufacturers, providers, and payers adopt a more integrated approach to strategy-one that aligns clinical evidence with distribution logistics, contractual terms, and patient support programs. Only through this integrated lens can stakeholders navigate the changing therapeutic ecosystem and identify sustainable pathways to deliver value.

A focused examination of how United States tariffs in 2025 reshaped pharmaceutical supply chains, procurement strategies, and distribution stability for retinal therapies

The introduction of tariffs and trade measures can create ripple effects across pharmaceutical supply chains, procurement strategies, and pricing negotiations. In 2025, United States tariff adjustments influenced how manufacturers and distributors planned inventory, negotiated contracts, and structured their import strategies, prompting a reassessment of cost drivers and contingency mechanisms. These policy changes contributed to elevated scrutiny of sourcing locations and accelerated discussions about regional manufacturing and nearshoring as ways to mitigate cross-border exposures.

As a result, contract negotiations between suppliers and health systems incorporated greater emphasis on supply-chain resiliency and clauses that address tariff pass-through, lead-time variability, and currency exposure. Distribution channels including hospital pharmacy, online pharmacy, and retail pharmacy adapted their procurement strategies to ensure continuity of supply, which in turn affected stockpile policies and fulfillment models. Clinicians saw changes in availability rhythms that required flexible scheduling and patient communication tactics to preserve adherence and outcomes.

Importantly, these tariff-related dynamics intersected with broader shifts in site of care, dosing frequency preferences, and payer reimbursement practices. Consequently, healthcare stakeholders placed a premium on transparency in cost composition and a stronger alignment between commercial teams and supply-chain functions to safeguard patient access while maintaining operational predictability.

Actionable segmentation insights revealing how indication, site of care, distribution channel, and dosing frequency shape clinical adoption and operational strategies for Eylea

Segmentation analysis illuminates nuanced adoption patterns and operational implications that inform clinical, commercial, and supply-chain decisions. Based on indication, Eylea's use spans Age-Related Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Diabetic Macular Edema, and Diabetic Retinopathy, each presenting distinct patient profiles, monitoring requirements, and long-term management goals that influence treatment cadence and follow-up intensity. For instance, chronic diabetic retinal disease pathways often require closer systemic coordination with endocrinology and primary care, whereas vein occlusion cases may demand more episodic intervention and imaging follow-up.

Based on end user, the market is examined across ambulatory surgical centers, hospitals, and ophthalmic clinics, with each setting presenting specific throughput constraints, staffing models, and reimbursement environments that affect regimen selection and scheduling. Distribution channel analysis encompasses hospital pharmacy, online pharmacy, and retail pharmacy, and highlights how procurement lead times, cold-chain logistics, and dispensing workflows shape clinic inventory practices and patient access points. Finally, dosing frequency segmentation considers as needed, bimonthly, and monthly approaches, which carry direct implications for adherence, clinic capacity, and long-term visual stability.

Taken together, these segmentation lenses reveal that strategic choices-ranging from contracting approaches to patient support services-must be tailored to the clinical indication, the primary site of administration, the chosen distribution pathway, and the dosing cadence to ensure both clinical effectiveness and operational efficiency.

Key regional intelligence synthesizing regulatory, payer, and delivery system differences across the Americas, Europe Middle East & Africa, and Asia-Pacific to inform tailored strategies

Regional dynamics exert powerful influence over regulatory pathways, payer structures, and clinical practice norms, requiring tailored approaches to commercialization and access. In the Americas, concentrated centers of retinal expertise and diverse payer models drive both high standards of evidence generation and complex contracting conversations, while supply-chain considerations emphasize regional distribution hubs and inventory resilience. Meanwhile, Europe, Middle East & Africa present a mosaic of regulatory frameworks and pricing mechanisms that necessitate differentiated engagement strategies with national health authorities and private payers.

In Asia-Pacific, rapid modernization of ophthalmic services, expanding private clinic networks, and growing investment in diagnostic infrastructure are accelerating adoption trajectories, yet heterogeneity in reimbursement and procurement processes requires nuanced market access planning. Across these regions, variations in predominant sites of care-ranging from hospital-centric models to ambulatory surgical centers and specialized ophthalmic clinics-alter operational priorities and influence decisions around dosing frequency and patient monitoring.

Consequently, a regionalized strategy that integrates regulatory intelligence, payer engagement, and localized patient support models is essential. By aligning clinical evidence with regional healthcare delivery realities and distribution capabilities, stakeholders can better navigate access barriers, optimize deployment of resources, and support consistent patient outcomes across diverse health systems.

Company level insights highlighting strategic differentiation through evidence generation, supply-chain resilience, and integrated service offerings in the retinal therapeutics space

Competitive dynamics in the retinal therapeutics space reflect a mixture of established biologics, biosimilars, and evolving delivery technologies, prompting companies to prioritize differentiation through outcomes data, patient support, and supply stability. Leading manufacturers have invested in head-to-head comparative studies, real-world evidence generation, and outcomes registries to substantiate clinical advantages and to inform payer conversations. Meanwhile, companies are strengthening their commercial propositions with services that reduce administrative burden for clinicians and patients, such as streamlined prior authorization support and coordinated injection visit pathways.

Supply-chain robustness has become a core differentiator, with industry players emphasizing multiple sourcing options, cold-chain integrity, and contractual flexibility to limit disruption from geopolitical or tariff-related shocks. Strategic partnerships between manufacturers and specialty distributors have surfaced as a method to optimize reach across hospital pharmacy, online pharmacy, and retail pharmacy channels while maintaining compliance with storage and handling requirements. Additionally, investment in digital tools for patient engagement and adherence monitoring is enhancing long-term outcomes and shaping competitive positioning.

Collectively, these company-level activities underscore a broader shift toward integrated solutions that combine clinical evidence, operational reliability, and services that reduce friction in the care pathway. For stakeholders, discerning these strategic priorities is essential when evaluating potential collaborators or benchmarking internal capabilities.

Actionable recommendations for industry leaders to align clinical evidence, supply resilience, and payer engagement while optimizing regional and site-of-care strategies

Industry leaders must take proactive steps to align clinical value with operational feasibility and payer expectations in order to sustain access and optimize patient outcomes. First, strengthen cross-functional alignment between commercial, medical affairs, and supply-chain teams to ensure that contracting terms, inventory strategies, and clinical messaging are coherent and responsive to tariff and procurement dynamics. This integrated approach reduces the risk of supply interruptions and clarifies responsibilities during periods of policy or logistical change.

Second, invest in robust real-world evidence programs and outcomes registries that demonstrate long-term visual benefits and inform payer discussions across indications such as Age-Related Macular Degeneration and Diabetic Macular Edema. Third, tailor patient support and adherence initiatives to dosing frequency realities-whether as needed, bimonthly, or monthly-to sustain visual gains while minimizing no-show rates and clinic bottlenecks. Fourth, expand distribution flexibility by cultivating relationships with hospital pharmacy, online pharmacy, and retail pharmacy partners to diversify fulfillment options and improve patient access points.

Finally, adopt a regionalized go-to-market posture that accounts for differences across the Americas, Europe, Middle East & Africa, and Asia-Pacific, aligning regulatory engagement, reimbursement strategies, and local stakeholder outreach. By operationalizing these recommendations, organizations can build resilience, demonstrate value, and accelerate appropriate patient access.

A clear and reproducible research methodology combining primary interviews, literature synthesis, and scenario analysis to ensure rigorous evaluation of clinical and operational dynamics

This research integrates multiple evidence streams to produce a comprehensive assessment of clinical, operational, and commercial dynamics. Primary research included structured interviews with retina specialists, pharmacy procurement managers, and health system operations leaders to capture firsthand perspectives on dosing cadence, site-of-care trends, and distribution challenges. Secondary research encompassed review of peer-reviewed literature, regulatory documentation, and publicly available clinical trial results to validate clinical endpoints and safety profiles across indications including Age-Related Macular Degeneration and Diabetic Retinopathy.

Analytical methods combined qualitative synthesis with comparative scenario analysis to explore implications of dosing frequency choices-spanning as needed, bimonthly, and monthly regimens-and to assess distribution channel impacts across hospital pharmacy, online pharmacy, and retail pharmacy pathways. Regional context was developed through targeted interviews and regulatory reviews across the Americas, Europe, Middle East & Africa, and Asia-Pacific to ensure findings reflect local practice patterns and access constraints. Throughout, rigorous quality control processes were applied to reconcile divergent inputs and to ensure that conclusions are grounded in verifiable evidence.

Transparency around methodology ensures that readers can interpret findings in light of data sources and analytical assumptions. For organizations seeking customized outputs, the methodology can be adapted to incorporate proprietary datasets, expanded primary interviews, or focused country-level appendices to support specific strategic decision needs.

A concise conclusion synthesizing clinical, operational, and regional imperatives to guide strategic decision-making for sustained patient access and therapeutic value

In conclusion, Eylea occupies a central role in contemporary retinal disease management, with clinical evidence and delivery models continuing to evolve in tandem. The interplay between dosing frequency preferences, site-of-care shifts, and distribution channel dynamics creates both challenges and opportunities for manufacturers, providers, and payers. Navigating this complex environment requires integrated strategies that bring together evidence generation, supply-chain resilience, and targeted payer engagement.

Moreover, regionally tailored approaches that acknowledge the distinct regulatory, reimbursement, and delivery realities across the Americas, Europe, Middle East & Africa, and Asia-Pacific will be essential for sustaining access and improving patient outcomes. As tariff and policy landscapes change, organizations must prioritize transparency in procurement and contractual arrangements to mitigate risk. By implementing the recommended actions-strengthening cross-functional coordination, investing in real-world evidence, diversifying distribution relationships, and adapting to regional nuances-stakeholders can preserve continuity of care and enhance long-term therapeutic value.

Ultimately, decision-makers who synthesize clinical insights with operational readiness will be best positioned to support patients and health systems through a period of continued transformation in retinal therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Eylea Market, by Indication

  • 8.1. Age-Related Macular Degeneration
  • 8.2. Branch Retinal Vein Occlusion
  • 8.3. Central Retinal Vein Occlusion
  • 8.4. Diabetic Macular Edema
  • 8.5. Diabetic Retinopathy

9. Eylea Market, by Dosage Frequency

  • 9.1. As Needed
  • 9.2. Bimonthly
  • 9.3. Monthly

10. Eylea Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Ophthalmic Clinics

11. Eylea Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Eylea Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Eylea Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Eylea Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Eylea Market

16. China Eylea Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc
  • 17.6. Adverum Biotechnologies Inc
  • 17.7. Alcon Inc
  • 17.8. Amgen Inc
  • 17.9. Apellis Pharmaceuticals Inc
  • 17.10. AstraZeneca plc
  • 17.11. Bausch Health Companies Inc
  • 17.12. Bayer AG
  • 17.13. Biogen Inc
  • 17.14. Eli Lilly and Company
  • 17.15. Genentech Inc
  • 17.16. GlaxoSmithKline plc
  • 17.17. Johnson & Johnson
  • 17.18. Kodiak Sciences Inc
  • 17.19. Merck & Co., Inc.
  • 17.20. Novartis AG
  • 17.21. Ono Pharmaceutical Co., Ltd
  • 17.22. Outlook Therapeutics Inc
  • 17.23. Pfizer Inc
  • 17.24. Regeneron Pharmaceuticals Inc
  • 17.25. Roche Holding AG
  • 17.26. Samsung Bioepis Co., Ltd
  • 17.27. Sanofi S.A.
  • 17.28. Santen Pharmaceutical Co., Ltd
  • 17.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL EYLEA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EYLEA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EYLEA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EYLEA MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EYLEA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EYLEA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EYLEA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EYLEA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES EYLEA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA EYLEA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EYLEA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EYLEA MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EYLEA MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EYLEA MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EYLEA MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EYLEA MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EYLEA MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EYLEA MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EYLEA MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EYLEA MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EYLEA MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EYLEA MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EYLEA MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EYLEA MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EYLEA MARKET SIZE, BY DIABETIC RETINOPATHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EYLEA MARKET SIZE, BY DIABETIC RETINOPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EYLEA MARKET SIZE, BY AS NEEDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EYLEA MARKET SIZE, BY AS NEEDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EYLEA MARKET SIZE, BY AS NEEDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EYLEA MARKET SIZE, BY BIMONTHLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EYLEA MARKET SIZE, BY BIMONTHLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EYLEA MARKET SIZE, BY BIMONTHLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EYLEA MARKET SIZE, BY MONTHLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EYLEA MARKET SIZE, BY MONTHLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EYLEA MARKET SIZE, BY MONTHLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EYLEA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EYLEA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EYLEA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EYLEA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EYLEA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EYLEA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EYLEA MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EYLEA MARKET SIZE, BY OPHTHALMIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EYLEA MARKET SIZE, BY OPHTHALMIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EYLEA MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EYLEA MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EYLEA MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EYLEA MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EYLEA MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EYLEA MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EYLEA MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EYLEA MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EYLEA MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EYLEA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS EYLEA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EYLEA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GCC EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GCC EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. GCC EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 98. GCC EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GCC EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPEAN UNION EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPEAN UNION EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. BRICS EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. BRICS EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. BRICS EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. G7 EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. G7 EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. G7 EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 113. G7 EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. G7 EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. NATO EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. NATO EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. NATO EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 118. NATO EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. NATO EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL EYLEA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. UNITED STATES EYLEA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. UNITED STATES EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. UNITED STATES EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. CHINA EYLEA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. CHINA EYLEA MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. CHINA EYLEA MARKET SIZE, BY DOSAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 129. CHINA EYLEA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. CHINA EYLEA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)